| TMO |
Report |
Revenue |
IN-LINE |
pred ~$11.80B vs. cons $11.716B |
MEDIUM |
| TMO |
Report |
Adjusted EPS |
BEAT |
pred ~$5.85 vs. cons $5.761 |
MEDIUM |
| TMO |
Report |
Organic revenue growth |
BEAT |
pred ~3.3% vs. cons 3.05% |
MEDIUM |
| TMO |
Guide |
FY2026 revenue |
UNCHANGED |
guide ~$47.3B-$48.1B vs. cons $47.768B |
MEDIUM |
| TMO |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$24.64-$25.12 vs. cons $24.851 |
MEDIUM |
| TMO |
Guide |
FY2026 organic revenue growth |
BETTER |
guide ~3%-4% vs. cons 3.21% |
MEDIUM |
| TMO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
LOW |
| TMO |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guide leaves modest implicit H2 pressure |
LOW |